Scarica l'app Stockscreener
16.39
0.31%
0.05
Generate Biomedicines Inc Borsa (GENB) Ultime notizie
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Generate Biomedicines Inc's (NASDAQ:GENB) Lock-Up Period To End on August 26th - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Shares Up 4.9%Still a Buy? - MarketBeat
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Generate Biomedicines (GENB) Stock Price, News & Analysis - marketbeat.com
Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines Shares Fall Following Q2 Financial Results - marketscreener.com
Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M - marketscreener.com
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business ... - Caledonian Record
Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Generate Biomedicines: Q2 Earnings Snapshot - marketscreener.com
Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash - TradingView
Generate Biomedicines, Inc. Q2 2026: Revenue $6.3M, EPS $(0.52) — 10-Q Summary - TradingView
GENB: Phase 3 clinical and AI-driven pipeline progress offset by rising R&D costs and net loss - TradingView
Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO - Stock Titan
Generate Biomedicines (GENB) Slips 4.4% to $13.85 as Biotech Uncertainty Weighs on SharesModified Schiff - vinanet.vn
Generate Biomedicines, Inc. (GENB) Return On Assets (TTM) - Zacks Investment Research
Generate Biomedicines (GENB) Rallies 4.36% as Biotech Sentiment ShiftsMomentum Stock Picks - vinanet.vn
Generate Biomedicines, Inc. Revenue Breakdown – NASDAQ:GENB - TradingView
JPMorgan Small Cap Value Portfolio's Generate Biomedicines Inc(GENB) Holding History - GuruFocus
Generate Biomedicines, Inc. (GENB) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Generate Biomedicines: Post Mega-Money IPO, Caution Is Warranted (NASDAQ:GENB) - Seeking Alpha
If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
Price to cash flow ratio of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Surges 5.96% – Support and Resistance Levels in FocusVolatility Stop - dars.gov.et
Price to sales forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Consolidates Near Upper Bound as Bulls Test ResistanceRegression Channel - dars.gov.et
Price to earnings forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Number of shareholders of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Edges Lower as Stock Hovers Near Support LevelsBPI Reversal - vinanet.vn
What Just Happened with Generate Biomedicines' IPO - Kavout | AI
Generate Biomedicines (GENB) Earnings Date and Reports 2026 - MarketBeat
Generate Biomedicines Inc. (GENB) Holds Steady Near Resistance Amid Low VolatilityHigh Dividend Factor - dars.gov.et
Generate Biomedicines (GENB) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Nvidia Invests in Biotech Company Generate Biomedicines - Intellectia AI
Significant Drop for Generate Biomedicines (GENB) as Shares Decl - GuruFocus
Generate Biomedicines Plunges As Rally Suddenly Unwinds - TipRanks
Generate Biomedicines Inc. Q1 2026 Earnings: Pre-revenue Biotech Reports Wider-than-Expected Loss, Stock Slightly DownCore Business Growth - dars.gov.et
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference - AOL.com
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday - The Motley Fool
EBITDA of Generate Biomedicines, Inc. – BX:GENB - TradingView
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):